Key facts
- Notable investors include SCE Freiraum Ventures, Technical University of Munich, Xpreneurs.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Onyx Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Onyx Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Onyx Biotech
Provider of mathematical modeling and standardized workflows designed to optimize and accelerate downstream process development for biopharmaceuticals. The company offers mathematical models and standardized workflows that reduce experimental effort and material consumption, enabling clients to shorten time-to-market and increase the success rate of therapeutic candidates.
- Sector
- Healthcare
- HQ
- Vaterstetten, Germany
- Founded
- 2024
- Employees
- 2
- Website
- onyx-biotech.com/
- Ownership
- Privately Held (backing)
Onyx Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Onyx Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Onyx Biotech in its N-PORT filings yet. We sweep new filings monthly.